Form 4: United Therapeutics COO Michael Benkowitz Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 10, 2025, Michael Benkowitz, the President and COO of United Therapeutics, executed stock options and sold shares of the company's common stock.
• These transactions were conducted under a Rule 10b5-1 trading plan established on August 7, 2024.
• Benkowitz exercised options to acquire 10,000 shares at a price of $111 per share.
• He then sold 10,000 shares at prices ranging from $345.6904 to $352.43 per share.
• The sales were executed in multiple trades at varying prices, with weighted average prices reported for each set of transactions.
• The shares are held in a trust beneficially owned by Benkowitz and his family members.
• After these transactions, Benkowitz directly owns 2,577 shares and indirectly owns shares held in trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard Form 4 filing related to pre-planned stock transactions.

Industry Context

This is a routine disclosure of insider trading activity, which is common for executives who receive stock options as part of their compensation. The use of a 10b5-1 plan indicates that the trading was pre-planned and not based on any inside information at the time of the trades.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares in the open market.

Key Dates